Market capitalization | $1.73b |
Enterprise Value | $608.03m |
P/E (TTM) P/E ratio | negative |
EV/Sales (TTM) EV/Sales | 3.77 |
P/S ratio (TTM) P/S ratio | 10.73 |
P/B ratio (TTM) P/B ratio | 2.95 |
Revenue growth (TTM) Revenue growth | 0.94% |
Revenue (TTM) Revenue | $161.10m |
EBIT (operating result TTM) EBIT | $-357.40m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
20 Analysts have issued a Arvinas, Inc. forecast:
20 Analysts have issued a Arvinas, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 161 161 |
1%
1%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -357 -357 |
15%
15%
|
Net Profit | -309 -309 |
4%
4%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
Head office | United States |
CEO | John Houston |
Employees | 445 |
Founded | 2013 |
Website | www.arvinas.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.